What's new?

Added 15 hours ago Drug news

FDA approves first medical device, Monarch external Trigeminal Nerve Stimulation System to treat ADHD

The FDA permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called...

Added 15 hours ago Drug news

Keytruda and Inlyta approved by FDA to treat first line renal cell carcinoma

Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase...

Added 15 hours ago Drug news

Successful COAST-X Phase III study of Taltz for the treatment of non-radiographic axial spondyloarthritis

Eli Lilly and Company announced that Taltz (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase...

Added 3 days ago Drug news

Soligenix reports enrollment stage for its pivotal phase III trial of SGX 942 for oral mucositis in head and neck cancer

Soligenix announced that it has reached a significant milestone in the Phase III clinical study (the "DOM-INNATE" study) for SGX...

Added 3 days ago Drug news

Results of long term study of tanezumab in patients with osteoarthritis

Pfizer Inc. and Eli Lilly and Company announced top-line results from a Phase III study evaluating tanezumab 2.5 mg and...

Added 4 days ago Drug news

NEJM has published a successful phase I/II trial of a lentiviral gene therapy for the treatment of infants with XSCID ( bubble boy disease)

Mustang Bio, Inc. announced that the New England Journal of Medicine has published data from St. Jude Children’s Research Hospital...

Added 5 days ago Drug news

FDA expands approval of PD-L1 IHC 22C3 pharmDx assay in NSCLC

Agilent Technologies announced that the FDA has updated its approval of the company’s PD-L1 IHC 22C3 pharmDx assay. The assay...